Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wowtab

This article was originally published in The Tan Sheet

Executive Summary

Yamanouchi Shaklee Pharma and J&J/Merck form an agreement for the development of an OTC product using Yamanouchi's Wowtab technology for quick-dissolving tablets that can be taken without water. J&J/Merck Consumer markets Mylanta and Pepcid AC antacids and stomach acid blockers. No OTCs using the Wowtab system are on the market; the J&J/Merck deal is the first such arrangement to be disclosed. Yamanouchi signed an agreement with Glaxo Wellcome recently for an Rx migraine therapy using the technology. Wowtab tablets are hard and stable, allowing bottle or blister packaging, but melt in the mouth in 15 seconds or less without water, the firm says...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS088549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel